The outbreak of the COVID-19 infection has led to the rapidity of vaccine usage in recent years. Emerging data indicate that the efficacy of vaccination against COVID-19 was about 95% in the general population, though its impact is impaired in patients with hematologic malignanc...
Being exposed to these cold-causing coronaviruses, anddeveloping immune memory cellsagainst them, may mean a stronger or quicker response to a COVID-19 vaccine. Some people have poor protective immune responses to COVID-19 vaccine candidates. These people may haveexisting immunityto the adenovirus ...
How obesity could create problems for a COVID vaccine. Nature 586, 488–489 (2020). Article CAS PubMed Google Scholar Salk, H. M. et al. Taxa of the nasal microbiome are associated with influenza-specific IgA response to live attenuated influenza vaccine. PLoS ONE 11, e0162803 (2016)...
The research is one of the world’s most comprehensive studies of the immune response against COVID-19 infection. It suggests vaccination is more effective than the body’s natural immune response following infection and shows the need to invest in new vaccine designs to keep pace withemerging C...
In research published Monday in the journal Lancet, scientists said that they found their experimental COVID-19 vaccine produced a dual immune response in people aged 18 to 55 that lasted at least two months after they were immunized.
Scientists have released the first real-world data from Africa on the effectiveness of two doses of AstraZeneca/ChaAd0x-1 COVID-19 vaccination, showing that while protective against SARS-CoV-2, immunity against the delta and omicron variants was lower, e
Most individuals (∼ 79.5 %, Table 1) were vaccinated with to 2–3 doses of an inactivated COVID-19 vaccine, which can induce low levels of SARS-CoV-2-specific IgA [21]. Because the interval between the last dose injection and the blood sample collection was >1 year, with a median...
In relation to COVID-19 (Coronavirus), a vaccine, however, is mostly likely around 12 months away from being available for widespread use due intense development process. The process is for a good cause, though, as it ensures the vaccine’s safety and efficacy once it’s in use. ...
In research led by vaccine experts at City of Hope, a novel COVID-19 vaccine candidate (COH04S1) has been found to also elicit a robust immune response to the mpox (formerly known as monkey pox) virus. Humans andnonhuman primateswho received COH04S1 generated an mpox virus (MPXV) cros...
BEIJING -- A Chinese inactivated COVID-19 vaccine candidate has been proved safe and tolerable and can induce a quick immune response, according to the findings from early and mid-stage clinical trials published in the journal The Lancet Infectious Diseases. ...